Guangzhou Innogen Pharmaceutical Group Co., Ltd.

广州银诺医药集团股份有限公司

02591.HK

Develops drug candidates for diabetes and metabolic diseases in China, including Efsubaglutide Alfa, approved in January 2025 for type 2 diabetes and in development for obesity, overweight, and MASH, with five pre-clinical candidates.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Distribution model
• Outsourced production (OEM / contract manufacturing)
• Negative operating cash flow
• Cash burn and runway
• Inventory level and ageing
• Investments and fair-value assets
• Adverse change after the track record
• Non-recurring gains and losses
• Chapter 18A biotech